GET DAILY SIGNALSVir Biotechnology (VIR): Can It Reach the $20 Target With +45% Upside?
Key Takeaways
- The central $20 target is the arithmetic mean of roughly ten current, verified analyst price targets, which range widely from $12 to $30.
- VIR recently traded near $13.8, a fresh 52-week high, after positive Phase 3 ECLIPSE 1 hepatitis delta data; reaching $20 implies roughly 45% additional upside, a substantial move.
- Supporting the bull case are a "best-in-disease" HDV data profile, a large cash position, and partnerships with Gilead Sciences (GILD) and Astellas.
- The biggest risks are binary clinical-readout risk, competition from Gilead and Mirum Pharmaceuticals (MIRM), a lack of commercial revenue, and an unusually wide spread in analyst targets.
- For deeper coverage of this ticker's Major News, Today's Price Move, Forecast, and Earnings, visit the dedicated pages.
- Explore Trending AI Robots to see how automated strategies are navigating this kind of catalyst-driven market.
Analyst Price Targets and Consensus View
The $20 figure is the arithmetic mean of the individual analyst price targets reviewed for this article, rounded from roughly $20.30. The underlying targets span about $12 to $30, and nearly every rating is a Buy or equivalent, reflecting broad, if not uniform, optimism. Among the higher targets are Barclays at $30 (maintained November 2026) and Morgan Stanley at $25 (Overweight), while Evercore ISI and H.C. Wainwright sit at $22. Mid-range targets include Goldman Sachs at $21, Raymond James at $19, and Needham at $18, with Bank of America and Leerink Partners at $17. TD Cowen's $12 is the low end of the range.
This wide range reflects genuine disagreement about how much of the hepatitis delta opportunity is already priced in and how to value early-stage oncology optionality. Bulls emphasize the combination's depth of viral suppression and convenient monthly dosing; more cautious analysts keep lower targets on competition, regulatory, and commercialization uncertainty. Notably, these targets do not represent a single official published consensus, and the mean is not a guarantee of future performance. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
VIR closed at $12.21 on November 6 and extended higher to roughly $13.8 in the following session after topline ECLIPSE 1 results, marking a fresh 52-week high. Reaching $20 would require a gain of about 45% from that level, a substantial move even after a strong run. The company holds roughly $901 million in cash and investments (before a separate $90 million Gilead upfront payment) and trades at a market capitalization near $2.1 billion.
The path toward $20 depends less on near-term earnings and more on clinical execution. The pivotal ECLIPSE 1 trial of elebsiran (an investigational small interfering RNA, or siRNA) plus tobevibart (a monoclonal antibody, or mAb) met its primary endpoint, with 44% of treated patients reaching undetectable virus plus normalized liver enzymes at week 48 versus 0% in the delayed-treatment group, and 79% reaching undetectable virus. A planned U.S. FDA filing around mid-2027, with ECLIPSE 2 and ECLIPSE 3 readouts expected in the first quarter of 2027, is the next major value inflection.
What Could Support a Move Toward the Target
The strongest support is the hepatitis delta data itself. Analysts such as Needham's Joseph Stringer described ECLIPSE 1 as a "clean win," while Leerink's Roanna Ruiz highlighted the potential for a "best-in-disease profile." The monthly two-injection regimen is also far more convenient than daily bulevirtide, a key competitive advantage. Expanded SOLSTICE data showing all 28 patients at week 96 with undetectable virus, plus early signs of a possible finite, "cure-like" response, add optionality.
Beyond HDV, the oncology collaboration with Astellas and VIR-5500 in prostate cancer, along with the Gilead collaboration (up to roughly $1.74 billion in potential milestone payments plus royalties), give the stock multiple shots on goal. A narrower-than-expected third-quarter loss (non-GAAP EPS of -$0.57 versus roughly -$0.74 expected) and a cash runway into the second half of 2028 also reduce near-term financing overhang. From what I see, the partnerships add meaningful optionality here.
What Could Prevent the Target From Being Reached
The principal risk is binary clinical outcomes: ECLIPSE 2 and ECLIPSE 3, and any oncology readouts, could disappoint. Competition is real, with Gilead's Hepcludex and Mirum's experimental brelovitug both vying for the HDV market, and regulators could take longer than expected. As a pre-revenue, clinical-stage company, VIR's valuation is heavily dependent on sentiment and future data, leaving little earnings floor. The wide analyst target range, from $12 to $30, is itself evidence of meaningful uncertainty, and a stock up sharply into a catalyst can correct quickly if follow-on data underwhelm.
Technical Levels and Market Structure
VIR has built an orderly recovery from a 52-week low near $5.22, trading above its 50-day average near $11 and 200-day average near $9.6. The prior 52-week high near $12.45, now broken, becomes the key breakout zone, while roughly $11 serves as the first major support level below the market. A decisive close below that area would signal a failed breakout, whereas holding above it keeps the longer-term recovery structure intact.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of about 12 months, though firms differ in their assumptions. The most important upcoming items are the ECLIPSE 2 and ECLIPSE 3 data readouts expected in the first quarter of 2027, the mid-2027 FDA filing timeline, further SOLSTICE durability data, and any updates on the Astellas oncology program. Investors should also watch analyst target revisions, partnership milestones, cash position, and competitive data from Gilead and Mirum. I'm watching this closely as the next catalysts approach.
Using AI Tools for Catalyst-Driven Names
Tickeron's AI Daily Buy/Sell Signals provide a practical way to track fast-moving stocks like this one. The signals draw on artificial intelligence to scan thousands of equities and ETFs, delivering Buy, Sell, or Hold indications based on technical shifts and market conditions. For names where clinical news can drive sharp gaps, this approach helps surface opportunities and monitor trends alongside core fundamental work.
Final Assessment
Can Vir Biotechnology reach $20? The arithmetic mean of the analyst price targets reviewed sits right around that level, but the range of $12 to $30 shows how divided the Street is. From a recent price near $13.8, the move requires roughly 45% further appreciation, supported by a compelling hepatitis delta data package, a strong cash position, and strategic partnerships, but constrained by binary clinical risk, competition, and the absence of commercial revenue. Whether $20 is reached will depend heavily on the early-2027 ECLIPSE readouts and progress toward an FDA filing, and no analyst target should be read as a forecast of certainty.
Exploring Tickeron AI Tools
In my own research process, I have found Tickeron's AI Daily Buy/Sell Signals helpful for staying on top of names with upcoming binary events. The platform applies AI to monitor market behavior across a broad universe, which can complement traditional analysis when timing matters. It is one of several tools I reference when evaluating clinical-stage opportunities.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
VIR in upward trend: price rose above 50-day moving average on October 26, 2026
VIR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend. In 35 of 39 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on VIR as a result. In 70 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for VIR just turned positive on October 27, 2026. Looking at past instances where VIR's MACD turned positive, the stock continued to rise in 36 of 41 cases over the following month. The odds of a continued upward trend are 88%.
The 10-day moving average for VIR crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Following a +23.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 205 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 128 of 159 cases where VIR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
VIR broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.103) is normal, around the industry mean (3.498). P/E Ratio (-6.898) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What are the Contribution Limits for a Roth IRA?
What is Tangible Net Worth?
What is Earnings Before Interest Depreciation and Amortization (EBIDA)?
Microsoft (MSFT) Stock Analysis: AI Leadership, Market Movements, and Financial Outlook May 28, 2025
Outperforming S&P - AI Trading Bots: Momentum Reaction
General Information
a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases
Industry Biotechnology
Advertisement